(VIANEWS) – SANOFI (SAN.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| SANOFI (SAN.PA) | €90.96 | 3.64% | 5.82% |
| CONTEXTVISION (CONTX.OL) | kr5.48 | 3.46% | 61.1% |
| VETOQUINOL (VETO.PA) | €99.50 | 0.97% | 8.99% |
| BIOMERIEUX (BIM.PA) | €102.25 | 0.77% | 10.61% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. SANOFI (SAN.PA)
3.64% Forward Dividend Yield and 5.82% Return On Equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 47.08B for the twelve trailing months.
More news about SANOFI.
2. CONTEXTVISION (CONTX.OL)
3.46% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and America. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary uses. Its products include Rivent that offers image enhancement and visualization solutions for ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, a 2D image enhancement product for handheld units; and Rivent 3D, an image enhancement solution for 3D ultrasound. The company also provides Altumira/Altumira Plus, an artificial intelligence-powered image enhancement product for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. ContextVision AB (publ) was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.34.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 16.12. Meaning, the purchaser of the share is investing kr16.12 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CONTEXTVISION’s stock is considered to be overbought (>=80).
Sales Growth
CONTEXTVISION’s sales growth for the current quarter is 29.8%.
More news about CONTEXTVISION.
3. VETOQUINOL (VETO.PA)
0.97% Forward Dividend Yield and 8.99% Return On Equity
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Earnings Per Share
As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.97.
PE Ratio
VETOQUINOL has a trailing twelve months price to earnings ratio of 20.02. Meaning, the purchaser of the share is investing €20.02 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.99%.
Volume
Today’s last reported volume for VETOQUINOL is 4463 which is 47.48% above its average volume of 3026.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 4, 2024, the estimated forward annual dividend rate is 0.85 and the estimated forward annual dividend yield is 0.97%.
Moving Average
VETOQUINOL’s worth is higher than its 50-day moving average of €96.14 and above its 200-day moving average of €98.97.
More news about VETOQUINOL.
4. BIOMERIEUX (BIM.PA)
0.77% Forward Dividend Yield and 10.61% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.01.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 33.97. Meaning, the purchaser of the share is investing €33.97 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.61%.
Moving Average
BIOMERIEUX’s value is above its 50-day moving average of €99.46 and above its 200-day moving average of €98.89.
More news about BIOMERIEUX.
